Rafael Holdings, Inc. owns commercial real estate assets and interests in preclinical and clinical stage pharmaceutical companies. The company is headquartered in Newark, New Jersey.
| Revenue (TTM) | 980,000 |
| Gross Profit (TTM) | 932,000 |
| EBITDA | $-35.23M |
| Operating Margin | -3838.00% |
| Return on Equity | -37.60% |
| Return on Assets | -22.10% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $1.52 |
| Price-to-Book | 1.54 |
| Price-to-Sales (TTM) | 118.86 |
| EV/Revenue | 88.36 |
| EV/EBITDA | 5.39 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -50.60% |
| Shares Outstanding | $51.21M |
| Float | $35.58M |
| % Insiders | 37.86% |
| % Institutions | 7.33% |
Volatility is currently expanding